Symbols / BNTC
BNTC Chart
About
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 380.91M |
| Enterprise Value | 194.22M | Income | -44.11M | Sales | — |
| Book/sh | 5.47 | Cash/sh | 5.50 | Dividend Yield | — |
| Payout | 0.00% | Employees | 19 | IPO | — |
| P/E | — | Forward P/E | -1.18 | PEG | — |
| P/S | — | P/B | 2.03 | P/C | — |
| EV/EBITDA | -4.02 | EV/Sales | — | Quick Ratio | 67.45 |
| Current Ratio | 67.69 | Debt/Eq | 0.53 | LT Debt/Eq | — |
| EPS (ttm) | -1.08 | EPS next Y | -9.42 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-05-14 | ROA | -22.41% |
| ROE | -33.50% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 34.25M |
| Shs Float | 17.83M | Short Float | 10.83% | Short Ratio | 14.24 |
| Short Interest | — | 52W High | 17.15 | 52W Low | 9.80 |
| Beta | 0.29 | Avg Volume | 182.77K | Volume | 186.75K |
| Target Price | $23.83 | Recom | Strong_buy | Prev Close | $10.72 |
| Price | $11.12 | Change | 3.73% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$23.83
Mean price target
2. Current target
$11.12
Latest analyst target
3. DCF / Fair value
$-2.29
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$11.12
Low
$17.00
High
$32.00
Mean
$23.83
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-24 | main | HC Wainwright & Co. | Buy → Buy | $32 |
| 2025-11-04 | main | HC Wainwright & Co. | Buy → Buy | $35 |
| 2025-11-04 | main | Citizens | Market Outperform → Market Outperform | $22 |
| 2025-09-24 | reit | JMP Securities | Market Outperform → Market Outperform | $20 |
| 2025-09-16 | main | Oppenheimer | Outperform → Outperform | $29 |
| 2025-05-19 | reit | HC Wainwright & Co. | Buy → Buy | $28 |
| 2025-05-15 | reit | JMP Securities | Market Outperform → Market Outperform | $20 |
| 2025-04-10 | main | JMP Securities | Market Outperform → Market Outperform | $20 |
| 2025-03-24 | reit | HC Wainwright & Co. | Buy → Buy | $28 |
| 2025-03-18 | reit | Citizens Capital Markets | Market Outperform → Market Outperform | $18 |
| 2025-02-21 | reit | HC Wainwright & Co. | Buy → Buy | $28 |
| 2024-12-13 | init | Baird | — → Outperform | $30 |
| 2024-12-03 | reit | Guggenheim | Buy → Buy | $17 |
| 2024-07-22 | init | Leerink Partners | — → Outperform | $13 |
| 2024-06-13 | init | Piper Sandler | — → Overweight | $30 |
| 2024-04-22 | main | JMP Securities | Market Outperform → Market Outperform | $16 |
| 2024-02-15 | main | JMP Securities | Market Outperform → Market Outperform | $10 |
| 2024-01-24 | main | JMP Securities | Market Outperform → Market Outperform | $8 |
| 2023-09-26 | main | JMP Securities | Market Outperform → Market Outperform | $6 |
- Durable BB-301 responses in muscular dystrophy to be detailed at MDA 2026 - Stock Titan Mon, 23 Feb 2026 12
- Benitec Biopharma (BNTC) Stock Analysis: Unpacking A 125% Potential Upside - DirectorsTalk Interviews hu, 19 Feb 2026 08
- BENITEC BIOPHARMA ($BNTC) Releases Q2 2026 Earnings - Quiver Quantitative hu, 12 Feb 2026 08
- Hedge funds owners may consider drastic measures as Benitec Biopharma Inc.'s (NASDAQ:BNTC) recent US$60m drop adds to long-term losses - simplywall.st Sat, 14 Feb 2026 08
- Wall Street Analysts Predict an 87.48% Upside in Benitec Biopharma (BNTC): Here's What You Should Know - Nasdaq Fri, 05 Dec 2025 08
- Liquidity Mapping Around (BNTC) Price Events - Stock Traders Daily Wed, 18 Feb 2026 04
- Benitec Biopharma stock soars after FDA Fast Track designation for OPMD drug - Investing.com Mon, 03 Nov 2025 08
- Hedge funds investors have a lot riding on Benitec Biopharma Inc. (NASDAQ:BNTC) with 37% ownership - Yahoo Finance ue, 18 Nov 2025 08
- Benitec Biopharma Inc. (BNTC) Stock Analysis: Exploring A 76% Potential Upside - DirectorsTalk Interviews hu, 09 Oct 2025 07
- Benitec Biopharma (NASDAQ: BNTC) to Share BB-301 OPMD Study Update in Investor Webcast - Stock Titan Sun, 02 Nov 2025 07
- Down 25.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Benitec Biopharma (BNTC) - Yahoo Finance Wed, 03 Dec 2025 08
- Why (BNTC) Price Action Is Critical for Tactical Trading - Stock Traders Daily Sat, 07 Feb 2026 03
- Benitec Biopharma Stock (BNTC) Opinions on $100M Stock Offering - Quiver Quantitative ue, 11 Nov 2025 08
- New gene therapy helps first OPMD patient swallow easier after 24 months - Stock Titan Sun, 11 Jan 2026 08
- $BNTC stock is up 2% today. Here's what we see in our data. - Quiver Quantitative Wed, 12 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 144223 | 1903133 | — | Purchase at price 12.85 - 13.44 per share. | SUVRETTA CAPITAL MANAGEMENT, LLC | Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-29 00:00:00 | I |
| 1 | 46141 | 538972 | — | Purchase at price 11.24 - 12.08 per share. | SUVRETTA CAPITAL MANAGEMENT, LLC | Beneficial Owner of more than 10% of a Class of Security | — | 2025-12-22 00:00:00 | I |
| 2 | 1481481 | 19999994 | — | Purchase at price 13.50 per share. | SUVRETTA CAPITAL MANAGEMENT, LLC | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2025-11-07 00:00:00 | I |
| 3 | 16497 | 211736 | — | Purchase at price 12.63 - 13.22 per share. | SUVRETTA CAPITAL MANAGEMENT, LLC | Beneficial Owner of more than 10% of a Class of Security | — | 2025-03-31 00:00:00 | I |
| 4 | 900000 | 11700000 | — | Purchase at price 13.00 per share. | SUVRETTA CAPITAL MANAGEMENT, LLC | Beneficial Owner of more than 10% of a Class of Security | — | 2025-03-26 00:00:00 | I |
| 5 | 103626 | — | — | Stock Gift at price 0.00 per share. | BUCHI J. KEVIN | Director | — | 2025-03-12 00:00:00 | D |
| 6 | 51813 | 199998 | — | Conversion of Exercise of derivative security at price 3.86 per share. | BUCHI J. KEVIN | Director | — | 2025-02-27 00:00:00 | D |
| 7 | 47520 | 527174 | — | Purchase at price 10.98 - 11.25 per share. | SUVRETTA CAPITAL MANAGEMENT, LLC | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2024-12-24 00:00:00 | I |
| 8 | 42000 | 403200 | — | Purchase at price 9.60 per share. | SUVRETTA CAPITAL MANAGEMENT, LLC | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2024-12-03 00:00:00 | I |
| 9 | 41436 | 416616 | — | Purchase at price 9.73 - 10.22 per share. | SUVRETTA CAPITAL MANAGEMENT, LLC | Director and Beneficial Owner of more than 10% of a Class of Security | — | 2024-11-20 00:00:00 | I |
Financials
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -42.06M | -22.19M | -18.28M | -17.54M |
| TotalUnusualItems | 693.00K | 39.00K | -418.00K | -243.00K |
| TotalUnusualItemsExcludingGoodwill | 693.00K | 39.00K | -418.00K | -243.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -37.92M | -21.75M | -19.56M | -18.21M |
| ReconciledDepreciation | 396.00K | 343.00K | 381.00K | 392.00K |
| ReconciledCostOfRevenue | 0.00 | 9.00K | 123.00K | |
| EBITDA | -41.37M | -22.15M | -18.70M | -17.78M |
| EBIT | -41.77M | -22.49M | -19.08M | -18.18M |
| NetInterestIncome | 3.29M | 904.00K | -33.00K | -32.00K |
| InterestExpense | 33.00K | 32.00K | 6.00K | |
| InterestIncome | -6.00K | |||
| NormalizedIncome | -38.61M | -21.79M | -19.14M | -17.96M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -37.92M | -21.75M | -19.56M | -18.21M |
| TotalExpenses | 41.77M | 22.49M | 19.16M | 17.93M |
| TotalOperatingIncomeAsReported | -41.77M | -22.49M | -19.08M | -17.85M |
| DilutedAverageShares | 36.21M | 18.36M | 1.39M | 480.69K |
| BasicAverageShares | 36.21M | 18.36M | 1.39M | 480.69K |
| DilutedEPS | -1.05 | -1.22 | -14.12 | -37.91 |
| BasicEPS | -1.05 | -1.22 | -14.12 | -37.91 |
| DilutedNIAvailtoComStockholders | -37.92M | -22.37M | -19.56M | -18.21M |
| NetIncomeCommonStockholders | -37.92M | -22.37M | -19.56M | -18.21M |
| OtherunderPreferredStockDividend | 0.00 | 619.00K | 0.00 | |
| NetIncome | -37.92M | -21.75M | -19.56M | -18.21M |
| NetIncomeIncludingNoncontrollingInterests | -37.92M | -21.75M | -19.56M | -18.21M |
| NetIncomeContinuousOperations | -37.92M | -21.75M | -19.56M | -18.21M |
| PretaxIncome | -37.92M | -21.75M | -19.56M | -18.21M |
| OtherIncomeExpense | 562.00K | -165.00K | -448.00K | -322.00K |
| OtherNonOperatingIncomeExpenses | -131.00K | -204.00K | -30.00K | -79.00K |
| SpecialIncomeCharges | 764.00K | 0.00 | ||
| OtherSpecialCharges | -764.00K | |||
| GainOnSaleOfSecurity | -71.00K | 39.00K | -418.00K | -243.00K |
| NetNonOperatingInterestIncomeExpense | 3.29M | 904.00K | -33.00K | -32.00K |
| TotalOtherFinanceCost | -3.29M | -904.00K | 33.00K | 6.00K |
| InterestExpenseNonOperating | 33.00K | 32.00K | 6.00K | |
| InterestIncomeNonOperating | -6.00K | |||
| OperatingIncome | -41.77M | -22.49M | -19.08M | -17.85M |
| OperatingExpense | 41.77M | 22.49M | 19.16M | 17.92M |
| OtherOperatingExpenses | -108.00K | 9.00K | 123.00K | |
| ResearchAndDevelopment | 18.33M | 15.61M | 12.77M | 11.27M |
| SellingGeneralAndAdministration | 23.43M | 6.99M | 6.38M | 6.65M |
| GeneralAndAdministrativeExpense | 23.43M | 6.99M | 6.38M | 6.65M |
| OtherGandA | 23.43M | 6.99M | 6.38M | 6.65M |
| SalariesAndWages | 291.00K | 613.00K | ||
| GrossProfit | 75.00K | 64.00K | -64.00K | |
| CostOfRevenue | 0.00 | 9.00K | 123.00K | |
| TotalRevenue | 0.00 | 0.00 | 75.00K | 73.00K |
| OperatingRevenue | 0.00 | 0.00 | 75.00K | 73.00K |
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| OrdinarySharesNumber | 26.25M | 10.09M | 1.65M | 480.69K |
| ShareIssued | 26.25M | 10.09M | 1.65M | 480.69K |
| TotalDebt | 849.00K | 284.00K | 559.00K | 811.00K |
| TangibleBookValue | 97.30M | 47.25M | 202.00K | 2.88M |
| InvestedCapital | 97.30M | 47.25M | 202.00K | 2.88M |
| WorkingCapital | 96.72M | 46.75M | -249.00K | 2.29M |
| NetTangibleAssets | 97.30M | 47.25M | 202.00K | 2.88M |
| CapitalLeaseObligations | 849.00K | 284.00K | 559.00K | 811.00K |
| CommonStockEquity | 97.30M | 47.25M | 202.00K | 2.88M |
| TotalCapitalization | 97.30M | 47.25M | 202.00K | 2.88M |
| TotalEquityGrossMinorityInterest | 97.30M | 47.25M | 202.00K | 2.88M |
| StockholdersEquity | 97.30M | 47.25M | 202.00K | 2.88M |
| GainsLossesNotAffectingRetainedEarnings | -839.00K | -892.00K | -830.00K | -1.25M |
| OtherEquityAdjustments | -839.00K | -892.00K | -830.00K | -1.25M |
| RetainedEarnings | -228.18M | -190.26M | -167.89M | -148.33M |
| AdditionalPaidInCapital | 326.31M | 238.40M | 168.92M | 152.45M |
| CapitalStock | 2.00K | 1.00K | 0.00 | 0.00 |
| CommonStock | 2.00K | 1.00K | 0.00 | 0.00 |
| PreferredStock | 0.00 | 0.00 | ||
| TotalLiabilitiesNetMinorityInterest | 2.30M | 4.96M | 4.26M | 3.09M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 495.00K | 38.00K | 284.00K | 559.00K |
| EmployeeBenefits | 0.00 | 38.00K | ||
| LongTermDebtAndCapitalLeaseObligation | 495.00K | 0.00 | 284.00K | 559.00K |
| LongTermCapitalLeaseObligation | 495.00K | 0.00 | 284.00K | 559.00K |
| LongTermProvisions | 38.00K | |||
| CurrentLiabilities | 1.80M | 4.92M | 3.98M | 2.53M |
| CurrentDebtAndCapitalLeaseObligation | 354.00K | 284.00K | 275.00K | 252.00K |
| CurrentCapitalLeaseObligation | 354.00K | 284.00K | 275.00K | 252.00K |
| PensionandOtherPostRetirementBenefitPlansCurrent | 426.00K | 475.00K | 472.00K | 400.00K |
| PayablesAndAccruedExpenses | 1.02M | 4.17M | 3.23M | 1.88M |
| CurrentAccruedExpenses | 754.00K | 2.68M | 2.02M | 1.39M |
| Payables | 268.00K | 1.49M | 1.21M | 493.00K |
| OtherPayable | 67.00K | 138.00K | 69.00K | 71.00K |
| AccountsPayable | 201.00K | 1.35M | 1.14M | 422.00K |
| TotalAssets | 99.59M | 52.21M | 4.46M | 5.97M |
| TotalNonCurrentAssets | 1.07M | 536.00K | 735.00K | 1.15M |
| OtherNonCurrentAssets | 62.00K | 97.00K | 135.00K | 185.00K |
| NonCurrentPrepaidAssets | 83.00K | 87.00K | 25.00K | 25.00K |
| NetPPE | 991.00K | 449.00K | 613.00K | 993.00K |
| AccumulatedDepreciation | -1.47M | -1.40M | -1.32M | -1.18M |
| GrossPPE | 2.46M | 1.85M | 1.93M | 2.17M |
| Leases | 24.00K | 24.00K | 24.00K | 24.00K |
| OtherProperties | 1.53M | 1.52M | 1.34M | 1.34M |
| MachineryFurnitureEquipment | 44.00K | 38.00K | 38.00K | 37.00K |
| BuildingsAndImprovements | 860.00K | 270.00K | 526.00K | 771.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 98.52M | 51.67M | 3.73M | 4.82M |
| OtherCurrentAssets | 628.00K | 516.00K | 1.18M | 741.00K |
| RestrictedCash | 113.00K | 63.00K | 13.00K | 14.00K |
| PrepaidAssets | 741.00K | 799.00K | ||
| Receivables | 33.00K | 229.00K | 55.00K | 3.00K |
| AccountsReceivable | 33.00K | 229.00K | 55.00K | 3.00K |
| CashCashEquivalentsAndShortTermInvestments | 97.74M | 50.87M | 2.48M | 4.06M |
| CashAndCashEquivalents | 97.74M | 50.87M | 2.48M | 4.06M |
| CashEquivalents | 0.00 | |||
| CashFinancial | 97.74M | 50.87M | 2.48M | 4.06M |
| Line Item | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|
| FreeCashFlow | -23.61M | -19.58M | -18.01M | -15.91M |
| IssuanceOfCapitalStock | 30.46M | 70.88M | 17.88M | 0.00 |
| CapitalExpenditure | -18.00K | -179.00K | -1.00K | -13.00K |
| EndCashPosition | 97.86M | 50.93M | 2.49M | 4.08M |
| BeginningCashPosition | 50.93M | 2.49M | 4.08M | 19.78M |
| EffectOfExchangeRateChanges | 49.00K | -8.00K | 412.00K | 204.00K |
| ChangesInCash | 46.88M | 48.45M | -2.00M | -15.91M |
| FinancingCashFlow | 70.48M | 68.03M | 16.02M | 0.00 |
| CashFlowFromContinuingFinancingActivities | 70.48M | 68.03M | 16.02M | 0.00 |
| NetOtherFinancingCharges | -2.32M | -5.89M | -1.87M | -3.23M |
| ProceedsFromStockOptionExercised | 42.34M | 3.04M | ||
| NetCommonStockIssuance | 30.46M | 70.88M | 17.88M | 0.00 |
| CommonStockIssuance | 30.46M | 70.88M | 17.88M | 0.00 |
| InvestingCashFlow | -18.00K | -179.00K | -1.00K | -13.00K |
| CashFlowFromContinuingInvestingActivities | -18.00K | -179.00K | -1.00K | -13.00K |
| NetPPEPurchaseAndSale | -18.00K | -179.00K | -1.00K | -13.00K |
| SaleOfPPE | 0.00 | |||
| PurchaseOfPPE | -18.00K | -179.00K | -1.00K | -13.00K |
| OperatingCashFlow | -23.59M | -19.40M | -18.01M | -15.90M |
| CashFlowFromContinuingOperatingActivities | -23.59M | -19.40M | -18.01M | -15.90M |
| ChangeInWorkingCapital | -2.73M | 1.17M | 714.00K | 1.04M |
| ChangeInOtherWorkingCapital | 73.00K | 80.00K | 121.00K | |
| ChangeInOtherCurrentLiabilities | -356.00K | -275.00K | -252.00K | -196.00K |
| ChangeInPayablesAndAccruedExpense | -2.46M | 980.00K | 1.43M | 1.09M |
| ChangeInAccruedExpense | -81.00K | 39.00K | 73.00K | |
| ChangeInPayable | -2.38M | 941.00K | 1.36M | 1.09M |
| ChangeInPrepaidAssets | -111.00K | 645.00K | -414.00K | 62.00K |
| ChangeInReceivables | 197.00K | -176.00K | -50.00K | 1.00K |
| OtherNonCashItems | -764.00K | |||
| StockBasedCompensation | 17.43M | 830.00K | 452.00K | 870.00K |
| UnrealizedGainLossOnInvestmentSecurities | 0.00 | 1.00K | 3.00K | 10.00K |
| DepreciationAmortizationDepletion | 396.00K | 343.00K | 381.00K | 392.00K |
| DepreciationAndAmortization | 396.00K | 343.00K | 381.00K | 392.00K |
| Depreciation | 396.00K | 343.00K | 381.00K | 392.00K |
| GainLossOnSaleOfPPE | 0.00 | |||
| NetIncomeFromContinuingOperations | -37.92M | -21.75M | -19.56M | -18.21M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BNTC
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|